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Prostate cancer is the most commonly diagnosed malignancy among US men. Men diagnosed 
with LPC, or cancer confined to the organ, are presented with many equally efficacious treatment 
options, such as radical prostatectomy surgery or radiation treatments, all with specific benefits 
and side effects.  Clinicians often, respecting autonomy in decision making, provide information 
but do not prescribe therapy, leaving treatment decision-making to patients and families.  
Understanding these factors and conflicts can help clinicians better guide patient treatment 
decisions.  The aims of this study are to:  (1) summarize the specific factors men take into 
consideration when making the LPC treatment decision, and (2) to identify inherent conflicts of 
this decision-making process.  Methodology included a content, conceptual, secondary data 
analysis of transcribed interviews from primary study of LPC decision-making.3 Concept 
categories were established through review of literature. Assessment of interview text using 
previously established translation rules ascertained factors and conflicts in LPC treatment 
decision process.   These were summarized and corroborated with expert review.  For the 
purpose of this study, factors have been categorized into absolute and relative factors.  Analysis 
reveals that several inherent, multifaceted conflicts persist among these men.  The conflicts that 
surfaced during secondary analysis of 31 individual interviews were thematically categorized 
iv 
 
into (1) fear of a reduction in quality of life, (2) time urgency, and (3) lack of trust in the 
physician.  Interestingly, if men have had experiences with traumatic family medical histories, 
especially non-prostate cancer, they were particularly fearful of cancer spread, and some even 
expressed inaccurate perceptions about prostate cancer treatments.  The most prominent conflict 
appeared to be a lack of trust in the physician and healthcare system, which is categorized further 
into four subthemes.  Many of these conflicts stem from profound past experiences that may 
require a more comprehensive assessment by clinicians then what is done in a typical doctor 
visit.  Future studies should focus on discovering realistic, cost-effective methods to address 
patient conflicts and fears.  If clinicians wish to individualize care, knowing men heavily rely on 
personal factors, they must understand the uniqueness of a man’s life experience will 
undoubtedly influence decision-making. 
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1.0 INTRODUCTION 
 
 
 
 
Prostate cancer is the most commonly diagnosed neoplasm in men, comprising 29% of all 
cancers, and is the second leading cause of cancer related deaths.1  Based on rates from 2003 to 
2005, approximately 16% of men (1 in 6) born today, will be diagnosed with cancer of the 
prostate at some point during their lifetime.  When examined by race, the incidence of prostate 
cancer among African American men compared to other ethnicities is significantly higher.  For 
Caucasian men, the incidence of prostate cancer is 156.7 per 100,000 men; Hispanic men 138 per 
100,000 men; Asian and Pacific Islander men 93.8 per 100,000 men; and American Indian and 
Alaskan Native men 73.3 per 100,000 men.  African American men, however, have an incidence 
rate of prostate cancer diagnosis remarkably greater at 248.5 per 100,000 men.  Furthermore, the 
death rate of prostate cancer for African American men is twice as high compared to the general 
population.2  Overall however, the incidence of diagnosis and mortality rate for men with 
prostate cancer has been decreasing since the early 1990s. 
 The majority of prostate cancer cases diagnosed are localized prostate cancer, or cancer 
confined to the organ.  When reviewing trends among US men from 2001 to 2005, only about 
4% of those diagnosed have prostate cancer that has already metastasized.  The 5-year survival 
rates for localized prostate cancer and metastatic prostate cancer is 100% and 31.7%, 
respectively. 2 
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Prostate cancer, unlike any other neoplasm, has a variety of treatment alternatives.  There 
are no randomized trials to support a greater survival rate of any option.  Furthermore, there is no 
clear consensus among the scientific community as to which treatment option is superior.  Each 
option has potential benefits along with specific unpleasant side effects.  Some clinicians provide 
information but do not prescribe therapy, leaving treatment decision-making to patients and 
families.  For a patient with no prior medical knowledge having just received the devastating 
diagnosis of cancer, decision-making related to LPC treatment can be a daunting task.  The 
patient has to consider all the factors in his life in order to make the best decision. 
Traditionally, prostate cancer has been a disease of older men, over 70 years of age, and 
thus, these men, with typical life expectancies of less than 15 years, will usually pass away from 
other comorbidities.3 However, the age of diagnosis is progressively declining due to 
improvement in prostate cancer detection through the widespread use of prostate specific antigen 
(PSA) screening.4  Today, instead of death from other comorbidities, men with prostate cancer 
experience the long-term side effects of the LPC treatment option they chose, or will die from 
the cancer itself, if it is not effectively treated. 
 Berry3 identifies factors that men may consider when making their treatment decision 
such as age, health status or the presence of comorbidities, work status, and family and marital 
status.  While knowledge of factors men consider is well established,5,6 men also may face 
certain conflicts that can make the treatment decision-making process difficult.  Conflicts can 
create fear or apprehension, potentially causing a standstill in the decision-making process.  
Factors and conflicts that contribute to a decision are very individualized to each man.  In some 
cases, a factor that, without difficulty, contributes to one man’s decision may present as a 
conflict for another man.  One example of this may be the consideration of side effects of each 
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treatment and how it affects a man’s quality of life.  Some men are certain urinary incontinence 
is not a desired side effect, causing them to choose radiation therapy.  Other men may be unsure 
which effects they are willing to live with, creating a halt in their decision-making process. 
 Because factors and conflicts appear to be closely related, this study will address both.  
The aims of this study are to:  (1) summarize the specific factors men take into consideration 
when making the LPC treatment decision through a review of the literature, and (2) to identify 
inherent conflicts of this decision-making process through a secondary data analysis of 
transcribed interviews from a primary study of LPC decision-making.3 
 Clinicians must become skilled at assisting men in identifying factors to aid them in their 
decision-making process.  Clinician responsibility is equally important in recognizing and 
resolving the conflicts men face during this process in order to decrease anxiety and increase 
satisfaction.  Studies have shown that when men experience more conflicts, or “factors that 
contribute to uncertainty”, the satisfaction with their treatment decision is lower.  Furthermore, if 
men have low decisional conflict, they were more likely to report a desire for a high level of 
participation with their physician in making the treatment decision.7   
 Patients’ conflicts must be identified, and clinicians must become capable of 
understanding the individual’s factors that contribute to their treatment decision. This may lead 
to a better individualized treatment plan and, expectantly, with more satisfying results for these 
men. 
 
 
 
 
 
 
3 
 
 
 
 
2.0 REVIEW OF THE LITERATURE 
 
 
 
 
2.1  PROSTATE CANCER OVERVIEW 
 
 
Prostate cancer presents as either localized or metastatic.  Localized prostate cancer is defined as 
cancer confined to the organ.  When the cancer extends past the borders of the prostate gland, it 
is labeled metastatic prostate cancer and spread may progress to adjacent structures including the 
seminal vesicles, the lymph nodes and throughout various anatomical structures, particularly 
bones.  Prostate cancer is staged T1 through T4 which categorizes the cancer into localized or 
metastatic (Table 2.1).  Assessment of the extent of cancer involvement is the best predictor of 
prognosis, especially when curative treatment is best offered to patients with localized disease.8  
For the purpose of this study, we will only focus on localized prostate cancer (LPC).  Table 2.1 
summarizes the cancer stages. 
 
 
Table 2.1: Cancer stages 9 
 
Stage Description 
T1 The tumor is not palpable but identified by needle biopsy 
T2 The tumor is palpable but confined to the prostate; may be in one or both lobes 
T3 The tumor is palpable and extends beyond the prostate; may involve seminal vesicles 
T4 The tumor is palpable and is fixed or invades adjacent structures 
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The majority of men with prostate cancer have no clinical symptoms; their cancer is 
typically detected through routine blood testing of prostate specific antigen (PSA) levels, digital 
rectal exams (DRE) and further recommended biopsies based on those results.  However, of 
those who do experience symptoms, localized disease can cause hematuria or urinary 
obstruction.  Cancer that spreads outside the organ may result in lower extremity edema from 
regional lymphatic obstruction or pain from bone metastasis.  Unpleasant urinary tract symptoms 
resulting from non-cancerous benign prostatic hyperplasia (BPH) may be similar to those found 
in prostate cancer and are common in older men.  While the presence of BPH creates a rise in 
PSA levels, it does not increase the risk of developing prostate cancer.10 
Prostate specific antigen (PSA) testing through blood tests is increasingly being used for 
screening and early detection of prostate cancer in middle-aged to older men.  PSA is a protein 
found in the blood of all men and may be produced by both benign and malignant prostate cancer 
cells.  However, PSA is not cancer specific and small amounts are normally leaked into 
circulation with usual concentrations less than 4 ng/ml.  Increased concentrations of PSA have 
been associated with certain non-cancer disorders or interventions, including BPH, prostatitis, 
vigorous massage or exercise, or biopsy of the prostate.8, 10  After cancer diagnosis, the PSA 
level is used to monitor the disease and examine for cancer relapse after treatment.  
Digital Rectal Examination (DRE) is routinely done by the trained clinician to assess for 
indurations or nodules on the prostate.  Its accuracy is user dependent and has poor 
reproducibility even among trained clinicians.  Though valuable when the patient’s age, family 
history of prostate cancer and PSA concentration are taken into account, many men with prostate 
cancer detected by this technique will typically have disease outside the gland at diagnosis.  Only 
about 3-6% of exams produce abnormal results that raise suspicion for cancer.10 
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If the results of the PSA test and/or DRE are abnormal, the next stage in diagnosis is a 
biopsy for tissue samples, usually with ultrasound guidance.8  If the samples are found to have 
cancerous cells, they are graded by the pathologist and are presented to the clinician and patient 
as a Gleason Score. 
The Gleason Score is an estimation of the tumor differentiation determined by comparing 
biopsy samples to five established histologic patterns.  The Gleason Score is the sum of two 
numbers: (1) the primary grade representing the majority of the tumor (>50%) is scored 
according to the most common pattern, and (2) the secondary grade representing <50% of the 
tumor is scored according to the second most common pattern as determined by the pathologist.9  
An increase in the score signifies an increase in tumor aggressiveness and a poorer prognosis.  
Although the Gleason Score contributes towards determining pathological extent of the disease, 
its setbacks include subjectivity, and it requires accurate interpretation by the pathologist.11 
  While there are many treatment options available for men with LPC, the most common 
include watchful waiting, radical prostatectomy surgery, external beam radiation therapy, 
brachytherapy, androgen deprivation therapy, and cryotherapy.  Because of the lack of 
randomized trials, the optimal treatment is not known, and preferred choices and 
recommendations vary widely.  All treatment options carry varying risks of complications and 
short-term and long-term side effects relating to urinary, bowel and sexual dysfunction.  Specific 
complications associated with each treatment option are discussed below.  Individual priorities 
are a factor in treatment decision.  Patients must weigh their values between quantity of life and 
cancer eradication, with quality of life and the side effects they are or are not willing to live 
with.10 
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Watchful waiting is an active plan to postpone intervention while following the patient 
regularly by monitoring PSA levels, changes in DRE, repeat biopsies or waiting for symptoms to 
develop.  Later interventions, whether curative or palliative, may be necessary depending on the 
patient’s preference, symptoms and clinical findings.8, 10  Older men or men with significant 
comorbidities, who have a life expectancy less than 10 years, with low PSA and Gleason Score, 
may tend to choose watchful waiting.  Because of the relatively indolent nature of prostate 
cancer, this is done to avoid side effects or a decrease in quality of life caused by treatment, with 
the expectation that the prostate cancer may not cause morbidity during their lifetime.12  
The surgical intervention, radical prostatectomy, involves removing the prostate, seminal 
vesicles, ampulla of vas, and possibly some pelvic lymph nodes, usually through a lower 
abdominal incision or through the perineum.8, 10  This surgery can be done laparoscopically or 
with robotic assistance, and attempts to preserve nerves for erectile function.  Advantageous 
characteristics of radical prostatectomy include the possibility of complete elimination of the 
cancer, providing it is localized, and it is generally well tolerated.  However, urinary, bowel, and 
sexual dysfunction are side effects most strongly associated with this procedure.  Long term 
urinary incontinence, urethral stricture, bladder neck contracture, and bowel and erectile 
dysfunction are all associated with radical prostatectomy and may significantly decrease a man’s 
quality of life.10 
With External Beam Radiation Therapy (EBRT), multiple doses of radiation from an 
external source are applied to the prostate over several weeks.  Potential benefits include 
possibly eliminating the cancer without exposing the patient to operative risks, such as bleeding, 
adverse affects from anesthesia, and death.  Conversely, it does not remove the gland and is not 
guaranteed to cure the disease.  EBRT requires 5 to 8 weeks of daily outpatient therapy.  Side 
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effects associated with EBRT include treatment related death, incontinence, proctitis, diarrhea, 
cystitis, erectile dysfunction, urethral stricture, bladder neck contracture, and bleeding.  EBRT is 
also contraindicated for those with inflammatory bowel disease because of the risk of bowel 
injury.10  
Brachytherapy includes the permanent implantation of approximately 80 to 120 
radioactive seeds into the prostate gland.  This procedure may eliminate the cancer, avoids the 
operative risk, and is done in a single, outpatient session.  However, it does not remove the 
prostate gland and its side effects include urinary retention, incontinence, impotence, cystitis or 
urethritis, and proctitis.  This is contraindicated in men with prior transurethral resection of the 
prostate (TURP).10  Though brachytherapy is becoming a more popular treatment for LPC, there 
are yet to be any long-term randomized clinical trials comparing brachytherapy to radical 
prostatectomy. 
The androgen, testosterone, in men has been known to be a contributing cause of prostate 
cancer.  Androgen deprivation therapy, through oral or injected drugs (eg. Finasteride) or 
through surgical removal of the testicles, can be used to lower or block circulating androgens.  Its 
potential benefits include avoiding the risk of prostatectomy or radiation therapy and it usually 
lowers PSA levels by slowing cancer progression.  The primary risk factors associated with this 
therapy is it does not remove the cancer.  Furthermore, androgen therapy may cause 
gynecomastia, impotence, diarrhea, osteoporosis, lost libido, hot flashes and “androgen 
deprivation syndrome”, which includes symptoms of depression, memory difficulties, and 
fatigue.10 
Cryotherapy includes destruction of the cancerous cells through rapid freezing and 
thawing using transrectal guided placement of probes, and the injection of freezing and thawing 
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gases.  Its benefits include possible elimination of the cancer, and it is completed in a single 
outpatient session.  Risks include incomplete eradication of the cancer because the gland was not 
removed, and side effects include impotence, incontinence, scrotal edema, pelvic pain, sloughed 
urethral tissue, prostatic abscess, and urethrorectal fistula.10 
 
 
 
2.2  DECISION-MAKING METHODS 
 
Before examining the specific factors men take into consideration for decision-making, it is 
worthy to consider the methods men use to make their decision.  A study by Steginga and 
colleagues describe non-systematic and systematic processes used by men when progressing 
through LPC treatment decision-making.13  Non-systematic processing is explained through 
heuristics, or an informal method of decision-making using a set of rules, particularly used to 
quickly come to a solution that is reasonably close to the best possible option.  Behaviors using 
the heuristic model include deferral of decision-making responsibility to the doctor, previous 
experience and memories, and lay beliefs about cancer treatment and causes.  Systematic 
processing is defined as the consideration of medical information, such as treatment side-effects, 
and the significance of clinical aspects of their cancer (stage and grade) when making a treatment 
decision.13 It is assumed that systematic processing is superior to non-systematic processing, and 
its use by patients is preferred by most clinicians.  However, an astounding 91% of men in the 
study conducted by Steginga and colleagues reported using non-systematic processes in their 
decision making.13  In most qualitative studies addressing factors in LPC treatment decision-
making, the research participants were all approached with similar statements or questions.  
Participants were usually asked to describe their treatment decision-making process, what factors 
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they had considered, and how they chose their treatment.  Also, men were asked what aspects 
had been helpful or unhelpful in making their decision, and concerns that surfaced.3, 13, 14 
 
 
 
2.3  FACTORS 
 
Analysis of the medical literature reveals a myriad of individualized factors that influence 
treatment decision-making in men with prostate cancer.  A study by Berry and colleagues at the 
University of Seattle titled, “Treatment decision-making by men with localized prostate cancer: 
the influence of personal factors,” specifically studied such global factors.3  The purpose of 
Berry’s study was to “systematically document meaningful and relevant aspects of treatment 
decision-making reported by men with localized prostate cancer.”3  The study results, presented 
in greater depth in Section 5: Discussion, concluded with several themes and aspects describing 
men’s decision making experience, including nine personal factors, the influential other, and a 
core process of “making the best choice for me.”  Personal factors identified were age; what I do; 
priorities; health status; personality; lifestyle; experiences; philosophy; and ethnicity.3 
 In order to define the process of decision making in further detail, this study includes the 
consideration of treatment decision factors.  These factors are defined as something the decision-
maker takes into consideration that contributes to or has an influence on the treatment decision.  
Certain factors can be helpful in making the treatment decision, while other factors can create 
conflicts and barriers for the individual.  Conflicts are defined as a state of uncertainty or 
distress, thus, impeding the decision-making process unless a resolution or compromise is made 
in a timely manner.  These can result from fear of negative outcomes or incompatibility of needs 
and desires.  Even so, conflicts are not uniformly barriers.  For example, the possibility of 
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impotence may be a barrier to decision-making for a man who is sexually active, but not 
necessarily so for men who are not.   
In order to better characterize these unique and personal factors, they were categorized 
into absolute factors and relative factors (Figure 2.1).  Absolute factors that affect decision-
making are present at the time of diagnosis and are essentially fixed throughout the course of the 
decision-making process.  These factors include (1) demographics, (2) LPC disease 
characteristics, and (3) current health status.  Relative factors, however, occur and affect 
decision-making after the LPC diagnosis has been presented to the patient.  These factors are 
grouped into (1) information they obtain, seek, and value, and (2) consideration of quality of life 
versus cancer eradication. 
 
 
 
 
Figure 2.1: The decision-making process.  The patient, represented by the inner sphere, considers 
individualized absolute and relative factors when making a treatment decision.  These factors 
may create conflict requiring resolution before a treatment decision can be made. 
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2.3.1  Absolute Factors 
 
 
An absolute factor existing at the time of diagnosis is the demographic characteristics of a man, 
which play an important role in treatment decision-making.  Characteristics found in literature 
that appear to have the largest role are age and life expectancy, ethnicity, work status, family 
status, and marital status.  In some cases, a man’s demographic standing may change (i.e. change 
of employment status, death of a spouse, etc.), but for most, demographics are essentially fixed 
for the course of the decision-making process.   
Age and life expectancy are factors largely used by clinicians in LPC treatment 
recommendations.  A patient is expected to live an additional ten to fifteen years if he is 
perceived as “young” and/or presents with few to no comorbidities.  In this case, physicians 
typically recommend aggressively treating the LPC with surgical or radiation options.  However, 
if the patient is not expected to live past ten years, physicians usually recommend watchful 
waiting anticipating the patient will pass away from unrelated diseases, and would rather the 
patient not experience decreased quality of life from LPC treatment side effects.15 
Conversely, longevity has been steadily increasing, and some researchers have theorized 
that “perceptions about age may inadvertently result in ‘undertreatment’ of elderly oncology 
patients.”15  How a patient factors age into their treatment decision is not always consistent with 
clinicians.  Furthermore, personal preferences vary widely when considering a patient’s family 
and marital status, which appears to play a large role in treatment decisions.  For men forty to 
fifty years of age, the value of quality of life usually supersedes the possibility of extending life, 
especially if they have a spouse and value sexual function.  The opposite appears to be true for 
individuals over fifty years of age, who are concerned about longevity, primarily if they have 
young children that require a decade or more of parental support.  However, when older men 
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have fulfilled life goals, such as familial responsibilities of raising children, they tend to focus 
again on quality of life, particularly if their spouse is still living.16 
Another demographic characteristic, ethnicity, is largely lacking in LPC research, but 
may be an absolute factor considered in decision-making.  African Americans are statistically 
shown to present more often with prostate cancer, have more aggressive disease, and have higher 
mortality rates than their Caucasian counterparts.  Despite this information, this group seemingly 
receives less aggressive therapy.  A study by Demark-Wahnefried and colleagues found that 
treatment options discussed by physicians vary by patient race, with African Americans being 
presented with fewer options.17  Furthermore, how African American men factor ethnicity into 
treatment decision is not well documented.  African Americans who do participate in trials 
concerning decision-making factors show they follow similar decision-making processes as other 
men, usually viewing age as a stronger factor then ethnicity.16 
Spouses frequently take initiative in seeking out additional information for the patient.  
Although their goals for therapy are similar to the patient’s, their preferences may be slightly 
different.  The significance of quality of life and side effects appear to be minimal for spouses, 
especially the importance of sexual function.  Spouses tend to value the total eradication of 
cancer as most imperative, which may be inconsistent with what the patient considers most 
important.6  Some studies have shown patients report feeling considerable pressure from their 
family members to aggressively treat their cancer.14, 18  However, the degree to which spouses 
influence the final treatment decision is unclear. 
Disease characteristics, such as the LPC tumor stage, grade, and PSA levels are of utmost 
consideration by the clinician when recommending a treatment decision.  Clinical characteristics 
are not as greatly considered by the patients as compared to other personal factors.  This may be 
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due to a poor understanding of medical terminology or biology.  However, some patients do 
factor this information into their treatment decision.  The clinical characteristics of prostate 
cancer considered to be most important by men with prostate cancer in making a treatment 
decision include the stage of their cancer (59%) and the low overall mortality rate associated 
with prostate cancer (45%).  Of slightly lower incidence is the consideration of prostate grade 
(Gleason score) (20%) and PSA level (21%) in their decision-making.13 
The presence of significant comorbidities is important to clinicians to determine the life 
expectancy of a patient with LPC.  The most common comorbidities considered tend to be 
hypertension, arthritis and musculoskeletal conditions, heart disease, urinary conditions and 
gastrointestinal disease.  In a study by Marr and colleagues, men with comorbidities tended to be 
“older, single and overweight, have lower incomes and less education, and be on Medicare or 
other non-private insurance than those without comorbid illness.”19  They discovered patients 
who had zero to two comorbidities were most commonly treated with radical prostatectomy.  In 
patients with three or more comorbidities, surgery was much less common.  At six or more 
comorbidities, hormonal therapy and watchful waiting comprised  almost half of the treatment 
plans.  This trend of treatment recommendations made by clinicians most likely results from the 
desire for good surgical candidates.  A history of stroke or heart disease is associated with 
significant perioperative risk due to decreased functionality of major organs.  These two groups 
in particular may be poor candidates for any surgery.19  Interestingly, however, a patient’s 
perception about their comorbidities may give them less apprehension about choosing the 
surgical option.  In a study by Berry and colleagues, men who have gone through surgery in their 
past, particularly major surgical procedures such as heart surgery, are much more willing to go 
through with surgery and have less anxiety then those who have never had major surgery.3  
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Those who have few to no comorbidities tend to have more apprehension about surgery and tend 
to choose “less aggressive” treatments, such as brachytherapy.3 
 
2.3.2  Relative Factors 
 
 
Men strongly consider the absolute factors already present at the time of their LPC diagnosis, 
such as demographics, disease characteristics and health status.  Relative factors, however, occur 
after the LPC diagnosis has been presented to the patient.  These factors can be particularly 
influential if they occur during a vulnerable period before a definitive treatment decision has 
been made.  Relative factors may contribute to the decision, or may impede the process by 
becoming a conflict and causing distress.  These factors are categorized into (1) the information 
men obtain, seek, and value, and (2) men’s consideration of quality of life versus cancer 
eradication. 
Many studies report high rates of information-seeking behavior about prostate cancer 
after their diagnosis.  Although men may report needing a great deal of information, the extent to 
which patients comprehensively or systematically process this information is limited.13 
Information sources, other than a physician, are most commonly sought from the following: the 
internet; non-medical persons, particularly friends and family; published written material; the 
media and celebrities; and anecdotes from others with cancer, whether prostate or non-prostate in 
nature.13 
Many men and their significant others actively collect as much information about the 
disease and its treatment options as possible.  Men often seek others who have prostate cancer to, 
first, determine how they decided on a treatment option, and, second, review the consequences of 
that decision.  In Berry’s study, 41 of 44 participants described hearing about or speaking with 
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other men who had prostate cancer.  This person is described as the influential other, or “an 
individual whose illness experience and/or story had explicit influence on the participant’s 
treatment decision.”3  Men describe influential others as people who have similar demographic 
characteristics, primarily age or disease characteristics.  
Patients who reported seeking out others with prostate cancer asked about that person’s 
individual experience and relate it to their own.  Often the people they spoke to had prostate 
cancers with very different clinical characteristics, such as advanced disease compared to their 
own localized disease.  Denberg and colleagues states “anecdotes exerted strong sway over 
patients’ feelings about their own prostate cancer, treatment preferences…primarily because 
patients viewed prostate cancer as a uniform entity, unaware of differences in prognosis based on 
tumor stage and grade.”20  For some, hearing anecdotes supported or justified their already 
chosen decision to have a particular treatment option.  Patients valued others’ experiences much 
more than reported population-based risk information.20 
In the study by Steginga and colleagues, 47% of men described their treatment based on 
others’ experience with cancer, whether positive or negative.  Often these examples were of 
people who had other cancers, such as breast cancer, where its clinical relevance compared to 
prostate cancer is low.  Through these examples, men exposed an inaccurate understanding of 
various cancer treatments, particularly chemotherapy and radiation therapy.  These men 
described unpleasant experiences of people they knew, who did not have prostate cancer, as a 
reason for having excluded radiation therapy.13  Another reason for patients ruling out radiation 
as a therapeutic option is the presence of inaccurate perceptions which arose before LPC 
diagnosis.  Examples of these perceptions were radiation would cause severe skin damage; it 
would cause other cancers; it would limit further options if it were to fail; and it was uncertain 
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compared to surgery which was more often associated with cure.  Patients’ desires to avoid such 
side effects were produced from stories of radiation used in non-prostate cancers, or in other non-
health related uses, such as its use of death and destruction in World War II.5 
Apart from these information sources, some of questionable validity, men still do place 
high value on the information provide by his urologist.  Interestingly, perceptions arise that 
clinicians who specialize in the treatment of prostate cancer, primarily urologist and radiation 
oncologist, are biased to their specialties and will more likely recommend a treatment in their 
specialty.  A study by Fowler and colleagues support this theory and concluded, “while 
urologists and radiation oncologists do agree on a variety of issues regarding detection and 
treatment of prostate cancer, specialists overwhelmingly recommend the therapy that they 
themselves deliver.”21  More significant is the extent in which patients use physicians’ 
recommendations when making their treatment decision.  Most clinicians treating patients with 
prostate cancer will make recommendations, but will leave the ultimate decision to the patient.  
Studies report that most men (96.2%) report their primary urologist is a source of information for 
decision-making.22  64.9% of patients recognized their urologist as a major influencing factor, 
but very few men indicate that their choice of treatment was based primarily on their physicians’ 
preference (6.1%).22 
Relative factors that present during the decision-making process largely consist of 
prioritizing quality of life and quantity of life.  Clearly, patients with cancer desire a treatment 
option that offers cancer eradication with a low side-effect profile.  However, because there 
remains a lack of consensus among medical professionals as to which treatment option is 
superior, men often must prioritize which of the two is most important, cancer eradication or 
quality of life.  It is still uncertain how these men balance the trade-offs of survival benefit of a 
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treatment with its morbidity. As discussed previously, men and their families report spending a 
considerable amount of time researching the efficacy of each treatment option using a multitude 
of resources.6  A study by Hall and colleagues reported that 64.5% of men indicated they chose a 
treatment on the basis of evidence that it was the best option to cure their cancer, while 24.8% of 
men selected a treatment with the best-side effect profile.22  On the other hand, Zeliadt and 
colleagues completed a database search of decision making in LPC which produced sixty-nine 
related articles.6  This review summarized that cancer eradication remains the patients’ primary 
concern in treatment decision.  However, there is a wide variation in the statistic of men that rank 
this as their top priority factor.  Some studies report that only 26% of patients selected treatment 
on the basis of evidence that it was the best procedure to cure their cancer, whereas other studies 
report the number of patients who value this as high as 98% of prostatectomy patients and 50% 
of brachytherapy patients.6  This shows there is considerable deviation in how men interpret 
information available about cancer control efficacy.  Other studies have found that men with 
perceived “good general health” appeared to place a higher value on quantity of life, whereas 
those already suffering from “poor general health” placed a higher value on quality of life.23  
Generally speaking, it is clear cancer eradication is an important issue for nearly all men. 
Equally important for many men is how treatment may impact their quality of life 
through possible side effects – the primary effects including impotence, bowel incontinence, 
urinary incontinence, and urinary retention.  Studied extensively, reports indicate that more than 
800 articles are available in literature concerning prostate cancer treatments and quality of life.  
Preferences are extremely individualized and the reported results of these preferences also vary 
widely.  Incontinence appears to have great influence on treatment decision in over half of 
prostate cases; impotence is typically less important, with fewer than 20% of men reporting it as 
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their top three attributes important to their decision.6  Other studies have found that the 
preservation of sexual function was more important among younger individuals below sixty 
years-old compared to those over seventy-five years-old.  Again, information is limited regarding 
how the methods men use to balance side effects when making their treatment decision.6 
 
 
 
2.4  SUMMARY 
 
The majority of men diagnosed with LPC have no clinical symptoms and their cancer is detected 
and diagnosed with blood PSA levels, DRE and biopsy.  Their cancer is then typically graded 
and categorized into a Gleason score and tumor stage.  A variety of treatment options are then 
presented to the patient, the most common including radical prostatectomy, brachytherapy, 
external beam radiation therapy, watchful waiting, androgren deprivation therapy and 
cryotherapy.  There is no clear consensus among clinicians as to which treatment option is 
superior, and, because recommendations vary widely, men must make their decision in a setting 
of uncertainty.  A man’s ability to process clinical information, such as disease characteristics, 
may be limited, and more often men begin to consider individual personal factors relevant to 
their life. 
A search of medical literature reveals a multitude of personal factors considered by men 
when making treatment decisions about early stage prostate cancer treatments.  Improved 
understanding of decision-making can be guided by further categorizing treatment decision 
making into absolute factors and relative factors.  Absolute factors are present at the time of 
diagnosis, and include demographics, LPC disease characteristics, and current health status.  
Relative factors occur after LPC diagnosis, and include the information men seek, and the 
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consideration of quality of life versus cancer eradication. Both absolute and relative factors hold 
the potential for creating conflict in the decision-making process.  The factors that may present 
as conflicts are unique to each man. Understanding, not only factors, but the absolute and relative 
factors that create conflict in treatment decision-making will help clinicians to better assist men 
with these difficult decisions. 
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3.0  METHODS OF DATA COLLECTION 
 
 
This study is a secondary analysis of data from thirty-one individual interviews collected by 
Donna L. Berry, PhD, RN and her research team at the University of Seattle (PRO08050045).  
The original study article, “Treatment decision-making by men with localized prostate cancer: 
the influence of personal factors,” contains methods of data collection and demographic 
information about all study participants.3  The research done by Berry also includes transcripts 
from five focus groups; however, that data is not included in this secondary analysis study which 
is focused only on the individual interviews. 
The overarching purpose was to better understand conflicts that may be inherent in the 
decision making process among men with localized prostate cancer. 
The specific aims include: 
1) Delineate absolute and relative factors inherent in the treatment decision making for 
early stage prostate cancer. 
2) Identify conflicts in the absolute and relative factors inherent in the treatment decision 
making process for early stage prostate cancer.  
Institutional Review Board (IRB) approval was obtained under exempt status from the 
University of Pittsburgh to conduct this secondary data analysis study (IRB # PRO08050045).  
All thirty-one transcripts were extensively reviewed and highlighted.  Relevant factors that 
created conflicts were noted in each interview.  Analysis data, along with exemplar quotes, were 
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organized into tables by the author and a second expert reviewer experienced in qualitative data 
analysis.  Thematic categorization was performed and final results were corroborated by expert 
review. 
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4.0  RESULTS 
 
 
The sample used in this study comprised of thirty-one men.  Demographic information for these 
participants is summarized in Table 1 of the original study article by Berry and colleagues (Note: 
Table 1 also includes demographic data from focus group participants not included in this 
secondary analysis study).3  The absolute and relative factors previously described in literature 
are clearly prominent in these interviews.  The conflicts that persisted among these transcripts as 
a result of various absolute and relative factors demonstrated how certain experiences impeded 
the man’s decision-making process.  For some men, the presence of conflicts created distress and 
difficulty in choosing a treatment option.  For others, their treatment decision was made without 
these complex dilemmas.  Themes of conflict among the thirty-one interviews were (1) a fear of 
a reduction in quality of life, (2) time urgency, and (3) a lack of trust in the physician.  
 
 
 
4.1  FEAR OF REDUCTION IN QUALITY OF LIFE 
 
A fear of a reduction in quality of life is a relative factor that becomes a conflict after diagnosis 
has been made (Figure 4.1).  Men are exposed to mass amounts of information about treatment 
options and their associated benefits and side effects.  Some may have difficulty sorting through 
this overload of knowledge, and some become apprehensive about the prospect of choosing what 
side effects were the least disagreeable for their case.   
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 Figure 4.1: A fear of reduction in quality of life (QOL).  Several examples of relative factors 
men experience are illustrated; these can lead to the conflict of a fear of reduction in QOL. 
 
 
The primary reason men feared a reduction in quality of life was twofold.  Although 
evidence is strong that not all treatments result in side effects, men still feared they would 
definitely obtain these effects.  Others were under an assumption that once side effects were 
obtained, they would persist indefinitely.  Even if men personally knew others who had suffered 
from side effects for a small amount of time after treatment, they assumed this would not be the 
case for them.  One respondent articulated these concerns in the following way:  
Incontinence, impotence, pain, possible damage to the rectum and bladder from radiation, and they seemed 
to be associated with just about any course except watchful waiting…so I was still pretty much up in the 
air, and I was finding that none of the procedures were absolutely free of possible undesired and long term 
impacts afterwards. 
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Another man stated, 
I feel with these different types of options then the most thing that was foremost in my mind was quality of 
life...if I was old, that wouldn’t be as big a factor, but at my age I don’t want to be going through a lot of 
changes for a long time, because, you know, I expect to live a long time…[urinary incontinence is] the 
thing that is really bad in my mind, you know, not having control…and I associate that with somebody 
that’s really ancient. 
 
Furthermore, those who valued a greater quality of life rather than quantity of life appeared to 
struggle more about which treatment option to choose.  Conversely, men who valued quantity of 
life and survival over quality of life appeared to be more confident in their decision-making and 
less conflicted.  Individuals may be initially conflicted in which they value more between quality 
or quantity of life.  Once men made a decision that quantity of life and survival is of utmost 
importance, they directed their focus more on the eradication of cancer and less on treatment side 
effects.  Justification of a particular treatment option is accepted by some patients provided it 
offers the highest chance of care. 
With the thought that maybe I can cure it with surgery, then that took precedence.  So, getting all the cancer 
cells is important – more important to me know then getting…preserving sex – sex life. 
 
There was also conflict related to quality of life from a perception that “once you decide, there is 
no turning back.”  One man described struggling with a commitment to therapy because of his 
perception of irreversibility of treatment. 
When you read and see TV, there’s a breakthrough everyday on something.  I’d hate to feel like I jumped 
into it and then a couple months down the road they say, “you know, all we have to do is a little laser deal 
and then it’s gone.”  And then I say, had I only waited a couple more months…There’s no reverse, you 
know, if I go through the treatment and for some reason my quality of life is shot, it’s shot forever. 
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4.2  TIME URGENCY 
 
The sense of time urgency from these men primarily stemmed from experiences of family past 
medical histories, the fear of cancer spread, and age.  Past experiences and age are absolute 
factors present at the time of diagnosis, but has become a conflict during the decision-making 
process (Figure 4.2).   
 
 
Figure 4.2: Time urgency.  Several examples of absolute factors men experience are illustrated; 
these can lead to the conflict of a sense of time urgency. 
 
 
Delving into these specific issues showed that these men were emotionally distraught, 
anxious and conflicted when applying family cancer experiences to their own.  In several cases, 
men had made treatment decisions influenced by experiences with family members who had 
suffered through illness.  Interestingly, the primary illnesses that would arise in stories from men 
26 
 
were of family with non-prostate cancers.  Men discussed treatments that created horrible, 
painful experiences for their family members, and used that as one reason for not choosing a 
certain treatment option, even if the two experiences were completely unrelated. They were not 
able to disassociate prostate cancer from other cancer types. 
My mother died of lung cancer…My nephew, he was 17, he had bone cancer of his leg, it metastasized to 
his lungs, and he lived about a year…Anyway, watchful waiting was not an option in my case. 
 
Patients who suffered through an experience with family members who had non-prostate cancers 
compared their two experiences closely, even if the only common denominator of the two cases 
was the word “cancer”.  Prostate cancer is typically understood to be a “slow-growing” cancer 
relative to other cancers, which is a clinical characteristic emphasized to patients by most 
urologists.  Men with early stage prostate cancers are usually allowed months before a treatment 
decision must be made.  However, when men had experiences of family members with non-
prostate cancers, men felt they had to make a decision immediately, perhaps to ease their 
apprehension and fear of metastasis or death.   
My daughter had pancreatic cancer…when she was diagnosed, she was given six months.  And it was about 
six months, that was about it...I think in this case there might have been an element of, “you better do 
something about this because look at [my daughter] and what happened to her.” 
 
In some cases, the anxiety related to decision-making created a conflict for that particular 
individual.  Anxiety from these experiences immobilized people without proper guidance and 
support from others, particularly clinicians.  One man described the source of conflicts in his 
experience, and how anxiety created a halt in his decision-making process. 
My mother-in-law died from cancer…I was there when she died…terror is the right word, that’s what the 
hell it is.  Because you have to deal with, “what are you letting go of?  What are you frightened of?  Is it 
physical pain, is it letting go?  Is it you don’t get to do some of the things you think you need to do?”  So 
there was a lot of anxiety there, that kind of thing.  When I was finally diagnosed, I think I was running on 
adrenaline for probably about two weeks or a month…I think there was some denial.  I think I just went 
away somewhere even though it was obvious something was, you know, serious business, you know, you 
have to make some goddamn decision. 
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Altogether, it appears that some men cannot disconnect LPC from other cancer types, and 
become especially conflicted if they had experiences with traumatic past family medical 
histories.  The anxiety of decision-making and a feeling of limited time “before something bad 
happens” created enormous amounts of conflict for these men.  They felt they must seek 
treatment immediately, or they may result in the same fate as their family members. 
Similarly, there was a time urgency to make a decision quickly because of the fear of 
cancer spread unrelated to past experiences with cancer. 
And going through the three to six months of hormone therapy…I began to be a little concerned about the 
spread of cancer…and most of what I had originally read did not talk about fast growing prostate cancer.  
In fact, I was told quite often that I would probably die of something other than prostate cancer, before 
prostate cancer would become symptomatic.  What I had began to find was that people did die of prostate 
cancer, and that it did metastasize, and that it could be faster acting then what I had been given to 
understand before. 
 
If men felt they were choosing the best possible treatment option to eradicate their cancer, they 
had a feeling of hope.  This seemed to alleviate some anxiety related to time urgency. 
I had hoped that if all the cancer were removed with the prostate, that I could rest more easy that there 
wouldn’t be any more cancer.  I understand that’s not necessarily a guarantee…But it at least was maybe 
something I could hope for. 
 
Previous discussion of time urgency stemmed from a feeling of anxiety because the man must 
quickly make a decision for fear of ill fate.  Other forms of time urgency include a hesitancy to 
make a decision because of age and desires for family.  As discussed earlier, age is typically a 
strong factor in decision-making taken into high consideration by both patients and clinicians.  
The consideration of age, in most cases, does not impede decision making.  A man’s perception 
of how “young” or “old” he is and his stage in life, related to family, are clear guides to which 
treatment options are best for that individual.  When a man is still considering the possibility of 
having children in his future, there created hesitancy in decision-making.   
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 One forty-six year-old man discusses a variation of time urgency from age and his desire for a 
family: 
I think another thing that’s really holding me up is that I don’t have any children even thought I know I’m 
old, but there’s a chance that I could have children…And so, you know, that kind of weighed heavily on 
me.  I think if I had kids, then that would change my decision, too. 
 
 
 
 
4.3  LACK OF TRUST IN THE PHYSICIAN 
 
 
Another overarching theme that caused conflict in decision making appears to be a lack of trust 
in the physician, primarily the urologist overseeing the patient’s case.  If the physician is viewed 
as a source of information, they are a relative factor in decision-making.  On the other hand, it is 
a patient’s past experience with healthcare as an absolute factor that is creating conflict (Figure 
4.3).  Four subthemes developed including (1) skepticism stemming from past negative 
experiences with healthcare, (2) a belief that physicians are biased to their specialties, and are not 
necessarily making the best choice for that man’s individualized case, (3) a struggle between 
following the physician’s advice versus following the man’s intuition, and (4) a divide between 
the physician and the patient because of race and socioeconomic status. 
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 Figure 4.3: Lack of trust in the physician.  Several examples of absolute factors men experience 
are illustrated; these can lead to the conflict of a lack of trust in the physician. 
 
 
 
Some men became skeptical of clinicians, possibly due to past negative experiences with 
healthcare, and were conflicted as to whether or not they should follow the physician’s treatment 
advice.  One patient discussed two past experiences where he had a condition that the initial 
physician advised operation, but after a second opinion, the condition was resolved from 
noninvasive procedures. 
Patient:  I’m very skeptical.   
Interviewer:  You saw there was an alternative to surgery and it worked, so you had a good experience with 
the alternative. 
Patient:  Yeah…My greatest fear is that something…would be removed unnecessarily…but a surgeon will, 
you know, at the slightest hint of infection he’ll remove it. 
 
Other men were skeptical of physicians because they simply lacked trust in the physician’s 
judgment.  
And then the more I was thinking about it, I want a second opinion too because I, I just wasn’t sure, my 
PSA was within that normal range, and I thought well maybe he’s just awfully anxious or eager. 
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Skepticism may also have stemmed from a lack of faith in the healthcare system because they 
may have had family members with conditions whose treatment was unsuccessful. 
I asked [Dr. 2] some questions of him like what was his batting average…because of what I watched with 
my family, and I’m the last [of them alive], I was a little bit concerned.  And I never really could get much 
out of him except he was a surgeon and he explained to me that there were about six or seven different 
ways of handling prostate cancer, and however we understand he was a surgeon…That meant that he 
wanted to remove my prostate. 
 
 Another concern was a perception that physicians were biased to their specialties and are not 
necessarily making the best choice for that man’s individualized case.  As shown in the original 
results of Berry’s research, she demonstrated that men often want the “best choice for me 
(2002).”  This theme also presents conflict for these men because if they felt that physicians were 
not personalizing their care to each case, they may not have been receiving the best possible 
treatment. 
And in the course of this internet stuff, of course I read that somebody had done a survey on urologists, 
most all of whom are surgeons, and 92% of them say that radical prostatectomy is the only way to go, and 
75 to 76% of [radiologists] say that radiation is the only way to go. 
 
Another man stated, 
I think I kind of drew the conclusion that urologists want to cut, radiologists want to seed implant, and 
cryogenicists want to freeze. 
 
One man discussed that when the physician made a treatment recommendation other than his or 
her specialty, such as a urologist specializing in surgery who recommended radiation, that the 
physician was more trustworthy. 
I fully expected [this urologist] to say well, prostatectomy is the way to go, and he didn’t, and so, you 
know, it’s like bringing your car to a mechanic and [the mechanic] saying well, all you really needed was to 
have this wire attached here, it doesn’t cost you anything, you know, in incontinence, when somebody goes 
contrary to the stereotype of a mechanic who’s going to say well you need a $500 part here.  So that put 
some credibility into what [the urologist] was saying. 
 
Furthermore, if the credibility of that physician was verified through some means, such as a 
physician’s reputation verified by other healthcare workers, the patient was more trusting of 
advice given to him. 
31 
 
[The first] urologist bet me $2000 I did not have prostate cancer…A few months later [my] biopsy was 
positive.  The urologist could never remember my name, read through my chart, mumbling, “That’s not 
good.”  After the urologist introduced treatment options, I told him the first decision I’m going to make is 
never come back here again…My wife is a nurse and checked out different doctors and UW, and we 
decided on the [second urologist] because when she said his name to the OR nurses they smiled and when 
she said the [first] surgeon’s name they looked weird and didn’t smile. 
 
Some men struggled between following the physician’s advice versus following their own 
intuition. 
I have over my life developed maybe a modified sense of being able to know what decisions to make based 
on, a sort of modified clairvoyance or whatever…I talked with [my second urologist] initially, and he was 
for the prostatectomy.  And I agreed at the time that he and I talked, but on the way back home I thought 
now, this is not right, this isn’t right, it’s not for me. 
 
One African American man discussed a divide between the physician and the patient because of 
race and socioeconomic status.  How this affected decision-making is unknown, but it does 
suggest the patient may be more skeptical of the physicians advice, and may have believed the 
physician was insensitive to the needs of certain populations. 
Some of the side effects were loss of sexual function…he talked about devices and stuff like that.  I worked 
as a third party insurance administrator, and I know that they don’t cover half that stuff.  All this stuff, good 
stuff that he’s talking about, that we can do this and we can do that – all that stuff costs money…And to me 
that was, it’s kind of unfair to tell people, to give people hope for something they can’t ever afford that 
insurance will not cover…I don’t think that that many people, especially African Americans, because they 
tend to be, you know, less financially stable, can take advantage of that…to even suggest that, it’s totally 
unfair…I think it’s more crushing at that point…I think to suggest that is a total disservice. 
 
He continued to state,  
I’m sure [the urologist] gives the same spiel to most of the patients…it’s not good, it’s not really a viable 
option for most individuals.  Especially if you’re talking about the African American community.  If you 
get them in there, I don’t think that you should feed them that type of information without giving them the 
whole story.  I mean, it’s just not fair to me.  
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5.0  DISCUSSION 
 
 
 
 
5.1  PRIMARY STUDY 
 
 
The original study done by Berry and colleagues aimed to, “systematically document meaningful 
and relevant aspects of treatment decision-making reported by men with localized prostate 
cancer.”3  While the original study focused on describing global factors, the purpose of this 
secondary analysis study was to more deeply evaluate research within these factors to describe 
the conflicts men undertake when making a treatment decision.  A separate study by Berry of 
treatment decision-making categorized themes of uncertainty to include: whether the respondent 
understood the options, the pros and cons of each option, the relative importance of the issues for 
his particular situation, and support/advice from others.  When more factors contributed towards 
uncertainty, patients had lower post decision-making satisfaction.7  Additionally, when men were 
assisted in retrieving more information they assumed a more active role and had lower levels of 
anxiety.24 Conflicts also appear to result from fear.  In the study by Steginga and colleagues, men 
described several fears which possibly conflicted with their decision-making progress.  Such 
fears included fear of the cancer spreading (37%), uncertainty about the probabilities of 
obtaining a cure (43%), uncertainty about the probabilities of side-effects (27%), uncertainty 
about the best treatment choice (25%), and fear of making a decision they would later regret 
(18%).13 
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Classification of nine personal factors are presented by Berry and colleagues, along with 
definitions and exemplar quotes, which include age, what I do, priorities, health status, 
personality, lifestyle, experiences, philosophy, and ethnicity.3  A core process of making “the 
best choice for me” was highlighted by the authors as the process when men take all information 
available, and individualizing the treatment decision to his case.  This process most likely 
develops in the majority of illnesses when the nature of uncertainty in a gold-standard treatment 
presents more patient autonomy in decision-making.  Also described is the aspect of an 
“influential other” illustrated by 43 of their 44 participants.  This influential other could be the 
physician, or other lay individuals such as friends, business associates, family members and 
celebrities, and their experiences or stories had influence on their treatment decision.  Men relied 
on these people to “widen their horizon, or move toward or away from a specific treatment 
modality.”3  
 
 
 
5.2  SECONDARY STUDY 
 
 
In this secondary analysis study, the influential other is a dynamic factor in decision-making, but 
hardly presents as a conflict.  Many men described seeking out others who had prostate cancer to 
ask of their treatment decision, but it was not evident if men were conflicted after speaking to 
others, or if they could not find such an individual.  What did produce conflict in men was a 
family member’s past medical history of cancer, particularly non-prostate cancers.  It is clear in 
some cases men cannot dissociate their LPC from other cancer types, and often compare the two 
experiences.  Even when men are knowledgeable about the “slow-growth” attribute of LPC, and 
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may even describe their cancer as “early stage”, men are still apprehensive during decision-
making for fear of cancer spread or treatment complications.   
Therefore, as clinicians, it is not only important to ask, “what is your past family medical 
history of cancer?”, but to also ask, “what is your experience with family members who had 
cancer?”  One study comparing fear of cancer spread before and after treatment shows that the 
fear of cancer recurrence significantly improved after receiving treatment.25  After undergoing a 
procedure, men may feel some element of control over their health and disease.  Conversely, 
though fear decreased after treatment, fear of cancer recurrence remained constant over time, and 
still produced burden after two years of treatment.25  Nevertheless, when cancer treatment 
misconceptions are present among patients, we must attempt to understand where they originate.   
The uncertainty of side effects, and struggling with a commitment to therapy because of a 
perception of irreversibility, is found extensively in medical literature to be a considerable factor 
during treatment decision-making.6  In this study, however, it is observed as a relative factor that 
creates conflict for men.  In Berry’s study, the importance of survival and/or its relationship to 
quality of life was addressed by 26 of the 31 individual interview participants.3  The most 
commonly addressed treatment complications were of incontinence, sexual dysfunction, and 
concerns for the spread of disease.3   
Interestingly, the aspect of decision-making that appeared to present the most conflict 
was a man’s relationship with his physicians and the healthcare system.  Once again, a man’s 
past experiences may influence his personality, perceptions, beliefs, and understanding of 
society.  The lack of trust in the physician is present in several dimensions, and these men appear 
conflicted with the validity of this essential information source.  Through the exploratory nature 
of this study, we as researchers can discover these conflicts as a source of uncertainty and 
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anxiety.  Yet how can clinicians also discover and, furthermore, address such issues?  
Skepticism, beliefs that physicians are specialty biased, recommendations going against personal 
intuitions, disconnection in patient-physician relationships due to race and socioeconomic status 
– these are all dilemmas that we can assess to provide a deeper, meaningful understanding of our 
patients.   
It is worthy to observe how trust and patient autonomy in decision-making are related.  A 
study by Kraetschmer and colleagues surveyed 601 patients in breast cancer, prostate cancer and 
fracture clinics, and overall found 6.3% had blind trust, 36.1% had high trust, 48.6% had 
moderate trust, and 9.0% had low trust.26  The authors continue to explain that blind trust was 
seen more in females, less educated, and elderly, and never found in those with post-secondary 
education.  Interestingly, more autonomous patients had relatively low levels of trust, passive 
respondents were more likely to have blind trust, and shared respondents had high but not 
excessive trust.  In prostate cancer, treatment decision-making is often a collaborative effort, and 
this study concludes “shared decision-making often accompanies, and may require, a trusting 
patient-physician relationship.26 
In many clinical situations, patients often ask the physician, “if you were me, what would 
you do?”  Berry recognizes this situation to be another way patients request a customized 
recommendation from their clinicians.3  Often physicians are concerned a straightforward answer 
could appear coercive or infringe in patient autonomy in decision-making, yet circuitous 
answers, or outright refusal to answer such questions could leave patients feeling unsupported, 
and promote a disconnection in the relationship. One study comments on this dilemma, and 
advises physicians to be attentive of the role of patients’ values, have an awareness of the force 
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of language, and portray a sense of empathy.  Furthermore, the authors state the medical facts are 
necessary, but without the discussion of values, they do not lead to a truly informed decision.27 
Through one man’s experience, there appears to be an estrangement between the 
physician and the patient due to race and/or socioeconomic status.  The physician is perceived by 
the patient as indifferent to the needs of specific populations, or is unaware, insensitive, or 
thoughtless about advice and recommendations given during doctor visits.  It has been reported 
that when African-American patients visit African-American doctors, they are more involved in 
medical decisions, have higher trust, and have higher satisfaction with their doctors then if they 
visited non-African-American physicians.  One study of 252 adults, and 31 physicians in 16 
primary care practices found that visits were two minutes longer and the patient’s affect was 
more positive when the physician and patient were of the same ethnic background.28  Further 
studies to understand factors to explain these differences are warranted, but one possible 
explanation is that patients and doctors communicate more effectively when they are of similar 
ethnic background.  Another explanation suggested by researchers is the formation of mistrust 
between patients and clinicians from the unethical practices in the infamous Tuskegee Syphilis 
Study.28 
Researchers suggest that solutions to increase ethnic diversity among physicians may be 
the most direct strategy to improve healthcare experiences for minorities.28  While this may be a 
straightforward answer, its feasibility is obviously questionable, and reliance on this solution 
alone is unrealistic.  An editorial by Delbanco supports this notion stating, “to what degree 
should we try to anticipate and cater to patients’ desires?..that ‘separate but equal’ should never 
be a goal, any move that results in segregating some patients and doctors from others could 
prove ruinous.”29  Clinicians of divergent ethnic backgrounds should instead attempt to 
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understand why these conflict persists, and proceed towards improved understanding of cultural 
sensitivity.  In another study of patient-physician communication in the presence of racial 
disparities among breast cancer patients, a physicians’ emotional support had no effects on 
outcomes.  Instead, the mitigation of racial disparities is influenced more by patient-empowering 
communication in terms of self-efficacy, knowledge, and coping.30  Overall, clinicians must be 
attentive of how they can improve the way they work with all patients, regardless of ethnicities.    
Both physician and patients have different anthologies of knowledge and experience, and 
drawing from both individual perspectives can yield the most satisfying care.29 
 
 
 
5.3  LIMITATIONS 
 
 
Secondary analysis of data from previous research presents as a limitation to this project.  As a 
result of the secondary analysis, interview questions were not tailored to the goals of this study.  
The aims of the original study by Berry and colleagues were to discover general, global factors 
taken into consideration by men during decision-making, and did not necessarily center on 
whether or not these factors created conflicts.  A secondary analysis of data can be beneficial, 
however, as it is more cost-effectiveness because subjects do not have to be recruited, the 
research requires less time, and it is an efficient use of data already collected.  Other limitations 
include a small sample size relative to quantitative studies.  However, saturation of themes 
associated with conflict was attained when analyzing these transcripts.  These interviews 
demonstrated some conflicts that may persist in men outside of the study, yet miss other possible 
conflicts not found in this sample.  Berry  also states that findings are “limited by the exploratory 
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nature of this study…Drawn from another population, the participants may have reported a 
different experience.”3 
Furthermore, the demographic information of this study group is not reflective of the 
population of the United States, limiting generalizability.  This sample includes few minorities, 
and continues to demonstrate how the study of minorities in prostate cancer research is strongly 
lacking.  College and graduate degree attainment in this group of participants is high compared 
to the United States population.  This is most likely due to a subject recruitment site that is 
located at an academic medical center where these men have access.  According to the U.S. 
Census Bureau in 2003, 8.9% of the population attained graduate degrees,31 whereas 43.2% of 
this study sample achieved a graduate degree.3  The majority of participants were retired (50%), 
married (70.5%) and made over $50,000 in annual income (50%).3  The decision-making 
abilities of this group may be more sophisticated compared to the general population, with 
possible greater proficiencies in processing and expressing information and experiences.  
However, it is interesting that these educated men still presented with conflicts, and found some 
difficulty resolving them.  Men of other demographic characteristics, such as lower education 
and income, may perceive and process the same information differently, consequently presenting 
with different, unique conflicts.  This study also specifically concentrates on men with localized 
prostate cancer, and does not address other malignancies.  Men with metastatic prostate cancer 
may have entirely different decision-making experiences due to the nature of the disease and 
differences in treatment options.  Overall, the generalization of these results to the population is 
precarious, and further quantitative studies with larger sample sizes, in multiple centers, are 
recommended.   
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6.0  CONCLUSION 
 
 
This secondary analysis of Berry’s data confirms her results of the personal factors found among 
these participants, along with evidence of the “influential other(s)” and “making the best choice 
for me.”  A deeper look into these individual interviews shows that inherent, multifaceted 
conflicts persist.  The exploratory nature of this study contributes more understanding and 
awareness to the field of decision-making in prostate cancer research.  However, we must then 
ask, what can practically be changed globally to address these dilemmas?  Many of these 
conflicts stem from profound past experiences that may require a more comprehensive 
assessment by clinicians then what is done in a typical doctor visit.   
This study further demonstrates how psychological aspects of the patient are equally as 
important as clinical characteristics.  More attention may be required in incorporating advanced 
communication skills and therapeutic discussion into medical academic curricula.  In some 
populations, the dissipation of sensitive patient-physician relationships second to race and 
socioeconomic status could be years from being sufficiently resolved. Clinicians should 
recognize this could be a particular barrier to effective medical counseling, and must tailor their 
communication style appropriately.  On the other hand, physicians are already demanded to hold 
a great deal of knowledge and skill to treat the patient, and to request further advanced trained in 
effective communication skills may not be practical.  Physicians are not independent entities in 
the healthcare system, and must draw from the resources available to them to fulfill a patient’s 
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psychological, emotional and educational needs.  Nurse educators are possible solutions to this 
dilemma, as they can spend more time with the patient to learn about the individual’s factors and 
conflicts, and address such issues appropriately.  This may relieve some pressure placed on the 
urologist, as many nurses are experienced in treating the holistic patient, and not just the physical 
disease.   
Conversely, the work force may not be sufficient enough to provide a national 
supplementation of nurses in this field.  Researchers, such as Berry, have approached this 
dilemma by creating a web-based program, called Personal Patient Profile - Prostate (P4), to aid in 
decision-making.32  Participants in this randomized, multisite study can choose to use P4 on a 
computer at home or on a touch-screen computer in the clinic; the overall study is currently 
ongoing and results are pending.32  The research and formation of decision aids is already well 
established in literature,33 although no one universal aid is currently in use.  The use of aids is to 
the discretion of the urologist, further illustrating the lack of consensus in this field of medicine.  
The time and cost required to improve outcomes by addressing such issues is unknown, but we 
can, however, appreciate the decision-making complexity found in LPC patients.   
Future studies should focus on discovering realistic, cost-effective methods to address 
patient conflicts and fears.  If clinicians wish to individualize care, knowing men heavily rely on 
personal factors, they must understand the uniqueness of a man’s life experience will 
undoubtedly influence decision-making. 
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